URGN Q1 2018 Earnings — UroGen Pharma Ltd. Revenue & Financial Results | Market Cap Arena

URGNUroGen Pharma Ltd.

$918M

Q1 2018 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$481,000+2431.6% YoY

Gross Profit

$51,00010.6% margin

Operating Income

-$14M-2835.8% margin

Net Income

-$13M-2782.1% margin

EPS (Diluted)

$-0.88

QoQ Revenue Growth

+47.1%

Cash Flow

Operating Cash Flow

-$10M

Free Cash Flow

-$10M

Stock-Based Comp.

$5M

Balance Sheet

Total Assets

$129M

Total Liabilities

$6M

Stockholders' Equity

$124M

Cash & Equivalents

$127M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$481,000	$19,000	+2431.6%
Gross Profit	$51,000	$1,000	+5000.0%
Operating Income	-$14M	-$4M	-285.5%
Net Income	-$13M	-$3M	-291.6%